Helthcare

• 

  Patanjali Ayurved & DS Group to Acquire Magma General Insurance: A foray into the Insurance Sector

  Patanjali Ayurved & DS Group are set to acquire Magma General Insurance from Sanoti Properties LLP for Rs 4,500 crore. This strategic move marks Patanjali’s entry into the general insurance sector. Read more about the impact and future implications of this deal.

• 

  Coforge Partners with ServiceNow to Launch GenAI CoE in Greater Noida

  Coforge partners with ServiceNow to launch a GenAI Center of Excellence (CoE) in Greater Noida, enabling businesses to leverage AI for automation, fraud detection, and digital transformation.

• 

  Glenmark Announces the Launch of Polyethylene Glycol 3350, Powder for Solution (OTC) in the US

  Glenmark launches Polyethylene Glycol 3350, Powder for Solution (OTC), an alternative to MiraLAX®, offering effective constipation relief. Learn more about its benefits, usage, and availability.

• 

  Glenmark Pharmaceuticals Launches Epinephrine Injection in the US, Secures CGT Exclusivity

  Glenmark Pharmaceuticals has launched a generic version of Epinephrine Injection in the US, providing a more affordable option for treating severe allergic reactions like anaphylaxis. This FDA-approved medication is bioequivalent to the branded version and comes with a 180-day Competitive Generic Therapy exclusivity, offering both cost savings and improved access to life-saving treatment.

• 

  Dr. Reddy’s Laboratories Receives EIR from USFDA for Hyderabad API Facility

  Dr. Reddy's Laboratories has received the USFDA's Establishment Inspection Report (EIR) for its Hyderabad API facility, signaling regulatory compliance. This comes alongside a strong Q3 FY25 performance, with a rise in net profit and sales, reinforcing the company's position in the global pharmaceutical market.

• 

  Lupin Receives USFDA Establishment Inspection Report for New Jersey Facility: A Positive Milestone Amidst Strong Financial Performance

  Lupin has successfully received the Establishment Inspection Report (EIR) from the USFDA for its Somerset facility in New Jersey. This milestone highlights the company’s dedication to maintaining high-quality manufacturing standards and strengthens its position in global pharmaceutical markets.

• 

  Granules India Board Approves Acquisition of 100% Stake in Senn Chemicals AG for Rs 192.5 Crore

  Granules India has announced its acquisition of Senn Chemicals AG, a Swiss CDMO specializing in peptide synthesis. This move strengthens Granules' position in the rapidly growing peptide therapeutics market, particularly in the development of next-generation anti-diabetic and anti-obesity treatments. The acquisition will enhance their R&D and manufacturing capabilities, driving innovation and expanding their global reach.

• 

  Orchid Pharma Gains 1.96% After Successful USFDA Inspection of Tamil Nadu Facility

  Orchid Pharma’s recent USFDA inspection success and the renewal of its EU GMP certification have strengthened its position in the global pharmaceutical market. However, despite regulatory milestones, the company reported a decline in financial performance for Q3 FY25.

• 

  Espire Hospitality Reports Impressive Growth in Q3 FY2024

  Espire Hospitality has delivered an outstanding financial performance for Q3 FY2024, with a 213.48% increase in net profit and a 259.42% rise in sales. The company’s strong recovery and strategic growth initiatives position it for continued success in the hospitality industry.

• 

  Glenmark Launches Latanoprost Ophthalmic Solution, Expanding Ophthalmic Portfolio in the U.S.

  Glenmark Pharmaceuticals has expanded its ophthalmic product portfolio with the launch of Latanoprost Ophthalmic Solution, a generic alternative to Xalatan. This new treatment provides an affordable option for managing glaucoma and ocular hypertension, offering the same effectiveness as the brand-name drug. Learn more about the product and its potential impact on the U.S. market.